Table 3.

Univariate and multivariate association of weight changes with major outcomes in CREDENCE. Entries are hazard ratio [95% confidence interval]

	hHF (n = 186)	hHF or CV Death (n = 264)	MACE (n = 299)	Non-fatal MI (n = 126)
Univariate
Gainers vs Stable	1.71 [1.19–2.40]	1.82 [1.35–2.42]	1.29 [0.95–1.73]	0.88 [0.50–1.45]
Losers vs Stable	1.69 [1.00–2.69]	1.60 [1.02–2.41]	1.90 [1.29–2.70]	2.02 [1.14–3.45]
Cana vs placebo	0.57 [0.43–0.77]	0.63 [0.50–0.81]	0.81 [0.65–1.02]	0.94 [0.66–1.33]
Multivariate
Gainers vs Stable	1.48 [1.03–2.10]	1.62 [1.19–2.16]	1.22 [0.89–1.64]	0.85 [0.48–1.41]
Losers vs Stable	1.50 [0.87–2.44]	1.53 [0.96–2.34]	2.03 [1.36–2.92]	2.15 [1.20–3.62]
Cana vs placebo	0.60 [0.44–0.81]	0.67 [0.52–0.86]	0.82 [0.65–1.03]	0.89 [0.63–1.28]
Sex (male)	0.91 [0.66–1.28]	0.99 [0.76–1.32]	1.29 [0.99–1.70]	1.13 [0.76–1.72]
Age (SD)	1.48 [1.26–1.75]	1.39 [1.21–1.60]	1.20 [1.06–1.36]	1.33 [1.09–1.62]
Baseline weight (SD)	1.29 [1.11–1.50]	1.15 [1.01–1.32]	0.95 [0.84–1.08]	0.94 [0.77–1.15]
Ln[UACR (mg/g)]	1.52 [1.29–1.80]	1.52 [1.33–1.76]	1.30 [1.15–1.48]	1.21 [1.00–1.47]
Smoking	1.23 [0.81–1.82]	1.07 [0.74–1.51]	0.90 [0.63–1.25]	1.27 [0.77–2.00]
Use of diuretics	1.34 [0.99–1.82]	1.19 [0.93–1.54]	1.08 [0.85–1.37]	1.28 [0.89–1.85]
Use of statins	1.33 [0.93–1.93]	0.94 [0.72–1.25]	0.97 [0.75–1.26]	1.62 [1.04–2.67]
Use of antithrombotics	1.50 [1.08–2.12]	1.49 [1.14–1.98]	1.65 [1.27–2.16]	1.58 [1.05–2.43]
Use of insulin	2.20 [1.47–3.35]	1.81 [1.30–2.55]	1.42 [1.05–1.94]	1.62 [1.02–2.63]
Use of metformin	0.96 [0.71–1.30]	0.88 [0.68–1.14]	0.87 [0.69–1.11]	0.89 [0.62–1.29]
Use of sulphonylureas	1.45 [1.01–2.08]	1.26 [0.92–1.71]	1.03 [0.76–1.38]	1.19 [0.75–1.84]
Use of GLP-1 RA	0.79 [0.36–1.53]	0.85 [0.43–1.50]	1.11 [0.61–1.84]	1.81 [0.84–3.43]

hHF, hospitalization for heart failure; CV, cardiovascular; MACE, major adverse cardiovascular events; MI, myocardial infarction; SD, standard deviation; UACR, urinary albumin-to-creatinine ratio; GLP-1 RA, glucagon-like peptide-1 receptor agonists